Company intelligence / Profile preview
Perha Pharmaceuticals
Roscoff, Bretagne, Franceperha-pharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Developing low molecular weight kinase inhibitors up to proof-of-concept in humans, with focus on correcting cognitive deficits associated with Down syndrome and Alzheimer's disease, as well as treating ototoxic hearing loss
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- Small molecules (low molecular weight kinase inhibitors)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
GO-DS21 consortium
Beyond the preview
Go deeper on Perha Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Perha Pharmaceuticals.